Q2 Earnings Estimate for LENZ Issued By HC Wainwright

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Equities researchers at HC Wainwright issued their Q2 2025 EPS estimates for LENZ Therapeutics in a report released on Thursday, March 20th. HC Wainwright analyst M. Caufield anticipates that the company will post earnings of ($0.60) per share for the quarter. The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($2.18) per share. HC Wainwright also issued estimates for LENZ Therapeutics’ Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($2.52) EPS, FY2026 earnings at ($2.18) EPS, FY2027 earnings at ($1.02) EPS, FY2028 earnings at $0.18 EPS and FY2029 earnings at $1.45 EPS.

LENZ Therapeutics (NASDAQ:LENZ) last issued its earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.04).

Several other brokerages have also commented on LENZ. Citigroup raised their price target on LENZ Therapeutics from $44.00 to $47.00 and gave the company a “buy” rating in a research note on Thursday, March 20th. TD Cowen assumed coverage on shares of LENZ Therapeutics in a report on Tuesday, March 18th. They issued a “buy” rating and a $60.00 price target for the company. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $41.67.

LENZ Therapeutics Stock Up 0.6 %

Shares of NASDAQ:LENZ opened at $26.66 on Monday. The business’s 50 day moving average is $24.22 and its 200 day moving average is $27.10. The stock has a market cap of $733.18 million, a P/E ratio of -5.59 and a beta of 0.58. LENZ Therapeutics has a 52-week low of $14.42 and a 52-week high of $38.93.

Institutional Investors Weigh In On LENZ Therapeutics

Institutional investors have recently bought and sold shares of the company. Wellington Management Group LLP lifted its holdings in shares of LENZ Therapeutics by 14.6% during the 4th quarter. Wellington Management Group LLP now owns 28,216 shares of the company’s stock valued at $815,000 after purchasing an additional 3,595 shares during the last quarter. California State Teachers Retirement System raised its stake in LENZ Therapeutics by 911.0% in the fourth quarter. California State Teachers Retirement System now owns 9,200 shares of the company’s stock valued at $266,000 after buying an additional 8,290 shares during the last quarter. Delta Investment Management LLC acquired a new stake in LENZ Therapeutics in the fourth quarter worth about $555,000. Rafferty Asset Management LLC purchased a new stake in shares of LENZ Therapeutics during the fourth quarter worth about $511,000. Finally, Paradigm Biocapital Advisors LP acquired a new position in shares of LENZ Therapeutics during the fourth quarter valued at about $22,243,000. 54.32% of the stock is currently owned by institutional investors and hedge funds.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.